NCT00561327

PPARgamma Activation by Losartan in Hypertensive Patients: The Importance of Losartan-Metabolites

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: —
• Sponsor: German Heart Institute · Academic / Other
• Sex: All
• Age: 19 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether losartan metabolites are effective in inducing PPARγ target genes in monocytes in losartan-treated patients.

Detailed description

The losartan metabolite EXP3179 potently induces the activity of the peroxisome proliferator-activated receptor γ (PPAR-γ) as a partial agonist in vitro. PPAR-γ is a nuclear hormone receptor and functions as a regulator of lipid- and glucose metabolism. PPAR-γ ligands improve insulin sensitivity and glucose tolerance, and reduce cardiovascular morbidity and mortality in diabetic patients. Angiotensin II receptor 1-blocking and PPAR-γ-activating properties of losartan metabolites in patients would markedly improve the pharmacological profile of losartan by combining anti-hypertensive and highly beneficial metabolic actions. We developed the following hypothesis: 1. Hypertensive patients chronically treated with losartan exhibit sufficient plasma levels of EXP3179 to activate PPARγ. 2. PPARγ target genes are induced in monocytes from losartan-treated patients.

Conditions

• Hypertension

Interventions

Type	Name	Description
DRUG	losartan	Daily treated with losartan 100mg for at least the past 2 months (retrospective, no new drug treatment/ intervention)

Timeline

• Start date: 2007-09-01
• First posted: 2007-11-20
• Last updated: 2007-11-20

Locations

1 site across 1 country: Germany